History

A list of downloadable documents created during development.

Background information

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination

Final appraisal determination

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation 2

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: letter to consultees and commentators

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation

Response to comments on pre referral remit and scope for STA sorafenib tosylate for advanced renal cell carcinoma

Response to comments on pre referral remit and scope for STA bevacizumab for metastatic renal cell carcinoma

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final matrix

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: response to consultee and commentators comments on the scope

Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft matrix

Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft scope

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final protocol